Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
Siltuximab may leads to higher WHO progression score (level 7 or above) D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Levilimab may leads to higher clinical improvement D28b compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether levilimab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether levilimab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in all‐cause mortality D60 or more compared with standard care/placebo (low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in adverse events ( compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes clinical improvement D60 or moree compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review